Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Brain Neoplasms 3Small Cell Lung Carcinoma 1Neoplasm Metastasis 1Lung Neoplasms 1Glioblastoma 1Fatigue 1Cognition Disorders 1Central Nervous System Carcinoma 1Breast Neoplasms 1

Interventions

Temozolomide 39Radiotherapy 18Lomustine 12Bevacizumab 11Carmustine 8Radiation 7Procarbazine 4Magnetic Resonance Spectroscopy 4Surgical Procedures, Operative 3pembrolizumab 2depatuxizumab mafodotin 2Tf-CRM107 2Specimen Handling 2Radiotherapy, Intensity-Modulated 2Drug Therapy 2Dihematoporphyrin Ether 2DNA Methylation 2Carboplatin 2ABT-414 2trans-sodium crocetinate 1tofacitinib 1sargramostim 1rindopepimut 1niraparib 1marizomib 1enzastaurin 1edotecarin 1contrast agent BR1 1cediranib 1carmustine, poliferprosan 20 drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Glioblastoma × Mental Status and Dementia Tests × Clear all
NCT01290939 2021-02-15

Bevacizumab and Lomustine for Recurrent GBM

European Organisation for Research and Treatment of Cancer - EORTC

Phase 3 Completed
592 enrolled
CNS

Brain Neoplasms, Cognition Disorders, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡